Document is current
Any future updates will be listed below
-
Authors
Ahmadi Bidakhvidi, Niloefar https://orcid.org/0000-0002-2225-0161
Giesen, Alexander https://orcid.org/0000-0002-3345-4573
Devos, Gaëtan https://orcid.org/0000-0002-6772-915X
Laenen, Annouschka https://orcid.org/0000-0002-1371-442X
Baldewijns, Marcella https://orcid.org/0000-0002-0882-2944
Koole, Michel https://orcid.org/0000-0001-5862-640X
Deroose, Christophe M. https://orcid.org/0000-0002-6080-1577
Everaerts, Wouter https://orcid.org/0000-0002-3157-7115
Joniau, Steven https://orcid.org/0000-0003-3195-9890
Goffin, Karolien https://orcid.org/0000-0002-7453-0229
- License Information
-
More Information
Article History
Received: 25 August 2025
Accepted: 14 October 2025
First Online: 13 November 2025
Declarations
:
: Christophe M. Deroose is/has been a consultant for (fees received by institution): Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO, Immedica Pharma, Molecular Partners, Nuclear Research and consultancy. His institution has received travel fees from: GE Healthcare, Sirtex. Karolien Goffin is/has been a consultant for (fees received by institution): Novartis, Bayer, Telix, PSI CRO, Full-Life Technologies, Blue Earth Theranostics, MSK. Her institution has received travel fees from: GE Healthcare, Bayer.
: This study was approved by the Ethics Committee Research UZ/KU Leuven (EC Research; study number S58827) and complied with the declaration of Helsinki.
: Informed consent was obtained from all individual participants included in this study.
